/ month Add to cart Lose weight, on your terms Personalized Weight Care Join the thousands of people who are losing weight with GLP-1 medications.
Our analysis indicates that between 20 and 30 percent of annual patients stop using the drugs, particularly those focused on weight loss, and these patients regain about two-thirds of the weight they lost
The protein-first eating strategy When your appetite is reduced by GLP-1 medication, every bite counts more
For Lipo C, subcutaneous is the industry standard for a reason
confirmed that overexpressed SLC1A3 in gastric cancer activates the PI3K/AKT pathway, upregulates the expression levels of Glucose transporter 1 (GLUT1), Hexokinase 2 (HK2), and Lactate dehydrogenase A (LDHA), and promotes the growth of gastric cancer, while treatment with the PI3K/AKT inhibitor LY294002 could inhibit the growth-promoting effect of SLC1A3 overexpression on gastric cancer